Gregory J Kato1. 1. Division of Hematology-Oncology, Department of Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Abstract
PURPOSE OF REVIEW: Sickle cell disease (SCD) afflicts millions worldwide. The simplicity of its single nucleotide mutation belies the biological and psychosocial complexity of the disease. Despite only a single approved drug specifically for the treatment of SCD, new findings reviewed from 2015 provide the direction forward. RECENT FINDINGS: The last year has provided a wealth of support for mechanisms affecting the red cell, hemolysis and vasculopathy, the innate immune system activation, blood cell and endothelial adhesiveness, central sensitization to pain, and chronic brain injury. The evidence supporting expanded use of hydroxyurea continues to mount. Many promising therapies are reaching clinical trial, including curative therapies, with more on the horizon. SUMMARY: Evidence is compelling that the use of hydroxyurea must be expanded by clinicians to gain the full pleiotropic benefits of this approved drug. Clinicians must become aware that severe acute and chronic pain has a biological and neurologic basis, and the understanding of this basis is growing. Researchers are testing investigational therapies at an unprecedented pace in SCD, and partnership between patients, researchers, and the private sector provides the most rapid and productive way forward.
PURPOSE OF REVIEW: Sickle cell disease (SCD) afflicts millions worldwide. The simplicity of its single nucleotide mutation belies the biological and psychosocial complexity of the disease. Despite only a single approved drug specifically for the treatment of SCD, new findings reviewed from 2015 provide the direction forward. RECENT FINDINGS: The last year has provided a wealth of support for mechanisms affecting the red cell, hemolysis and vasculopathy, the innate immune system activation, blood cell and endothelial adhesiveness, central sensitization to pain, and chronic brain injury. The evidence supporting expanded use of hydroxyurea continues to mount. Many promising therapies are reaching clinical trial, including curative therapies, with more on the horizon. SUMMARY: Evidence is compelling that the use of hydroxyurea must be expanded by clinicians to gain the full pleiotropic benefits of this approved drug. Clinicians must become aware that severe acute and chronic pain has a biological and neurologic basis, and the understanding of this basis is growing. Researchers are testing investigational therapies at an unprecedented pace in SCD, and partnership between patients, researchers, and the private sector provides the most rapid and productive way forward.
Authors: Enrico M Novelli; C Elizabeth Sarles; Howard Jay Aizenstein; Tamer S Ibrahim; Meryl A Butters; Anne Connelly Ritter; Kirk I Erickson; Caterina Rosano Journal: Psychiatry Res Date: 2015-04-25 Impact factor: 3.222
Authors: Jon A Detterich; Roberta M Kato; Miklos Rabai; Herbert J Meiselman; Thomas D Coates; John C Wood Journal: Blood Date: 2015-06-02 Impact factor: 22.113
Authors: John H Baird; Caterina P Minniti; Jung-Min Lee; Xin Tian; Colin Wu; Mary Jackson; Shoaib Alam; James G Taylor; Gregory J Kato Journal: Br J Haematol Date: 2014-11-06 Impact factor: 6.998
Authors: Anthony M Alvarado; Kendra M Ward; Devin S Muntz; Alexis A Thompson; Mark Rodeghier; Bo Fernhall; Robert I Liem Journal: J Pediatr Date: 2014-12-02 Impact factor: 4.406
Authors: Alister P W Funnell; Paolo Prontera; Valentina Ottaviani; Maria Piccione; Antonino Giambona; Aurelio Maggio; Fiorella Ciaffoni; Sandra Stehling-Sun; Manuela Marra; Francesca Masiello; Lilian Varricchio; John A Stamatoyannopoulos; Anna R Migliaccio; Thalia Papayannopoulou Journal: Blood Date: 2015-05-27 Impact factor: 22.113
Authors: Veronica van der Land; Henri J M M Mutsaerts; Marc Engelen; Harriët Heijboer; Mark Roest; Martine J Hollestelle; Taco W Kuijpers; Paul J Nederkoorn; Marjon H Cnossen; Charles B L M Majoie; Aart J Nederveen; Karin Fijnvandraat Journal: Br J Haematol Date: 2015-10-22 Impact factor: 6.998
Authors: Fiona C Brown; Ashlee J Conway; Loretta Cerruti; Janelle E Collinge; Catriona McLean; James S Wiley; Ben T Kile; Stephen M Jane; David J Curtis Journal: Blood Date: 2015-10-08 Impact factor: 22.113
Authors: Bidossessi Wilfried Hounkpe; Maiara Marx Luz Fiusa; Marina Pereira Colella; Loredana Nilkenes Gomes da Costa; Rafaela de Oliveira Benatti; Sara T Olalla Saad; Fernando Ferreira Costa; Magnun Nueldo Nunes dos Santos; Erich Vinicius De Paula Journal: Sci Rep Date: 2015-12-09 Impact factor: 4.379
Authors: Quan Li; Eric R Henry; James Hofrichter; Jeffrey F Smith; Troy Cellmer; Emily B Dunkelberger; Belhu B Metaferia; Stacy Jones-Straehle; Sarah Boutom; Garrott W Christoph; Terri H Wakefield; Mary E Link; Dwayne Staton; Erica R Vass; Jeffery L Miller; Matthew M Hsieh; John F Tisdale; William A Eaton Journal: Proc Natl Acad Sci U S A Date: 2017-01-17 Impact factor: 11.205
Authors: Giuseppe Cataldo; Mary M Lunzer; Julie K Olson; Eyup Akgün; John D Belcher; Gregory M Vercellotti; Philip S Portoghese; Donald A Simone Journal: Pain Date: 2018-07 Impact factor: 7.926